Canada Pension Plan Investment Board Has $4.41 Million Position in United Therapeutics Corporation (UTHR)
Canada Pension Plan Investment Board decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 49.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,592 shares of the biotechnology company’s stock after selling 37,100 shares during the period. Canada Pension Plan Investment Board owned approximately 0.09% of United Therapeutics Corporation worth $4,405,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in UTHR. Eagle Global Advisors LLC bought a new position in United Therapeutics Corporation during the 2nd quarter valued at about $206,000. TLP Group LLC bought a new position in United Therapeutics Corporation during the 2nd quarter valued at about $246,000. HPM Partners LLC lifted its stake in United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 15 shares during the period. Fort L.P. lifted its stake in United Therapeutics Corporation by 5.2% during the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 99 shares during the period. Finally, Prospera Financial Services Inc bought a new position in United Therapeutics Corporation during the 2nd quarter valued at about $277,000.
Shares of United Therapeutics Corporation (UTHR) opened at $118.58 on Wednesday. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89. The company has a market cap of $5,174.52, a PE ratio of 10.56 and a beta of 1.38.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same quarter in the prior year, the firm earned $4.23 EPS. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. analysts predict that United Therapeutics Corporation will post 11.92 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/canada-pension-plan-investment-board-has-4-41-million-position-in-united-therapeutics-corporation-uthr/1704319.html.
UTHR has been the topic of several research analyst reports. ValuEngine upgraded shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. TheStreet cut shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Cowen and Company restated a “hold” rating and set a $129.00 target price on shares of United Therapeutics Corporation in a research note on Friday, October 27th. Finally, HC Wainwright restated a “hold” rating and set a $95.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, October 26th. Five research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $132.82.
In related news, CEO Martine A. Rothblatt sold 1,235 shares of the stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $131.95, for a total value of $162,958.25. Following the completion of the sale, the chief executive officer now directly owns 2,304 shares of the company’s stock, valued at approximately $304,012.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,260 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $121.46, for a total transaction of $153,039.60. Following the completion of the sale, the chief executive officer now directly owns 1,400 shares of the company’s stock, valued at $170,044. The disclosure for this sale can be found here. Insiders sold a total of 18,053 shares of company stock valued at $2,234,661 over the last three months. 7.80% of the stock is currently owned by insiders.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.